. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Eur J Cancer. 2019 Jul 17;118:58–66. doi: 10.1016/j.ejca.2019.05.033

Table 5.

Analysis of EFS and OS for 39 patients with stage I focal anaplastic Wilms tumor according to treatment

Factor	Category	N	4-year EFS (95% CI)	P-value²	4-year OS (95% CI)	P-value²
Doxorubicin	Yes	11	100%	0.13	100%	0.47
Doxorubicin	No	28	89.1% (77.1–100)	0.13	96.4% (89.3–100)	0.47
Radiation	Yes	11	100%	0.06	100%	0.43
Radiation	No	28	89.1% (77.1–100)	0.06	96.4% (89.3–100)	0.43
Doxorubicin + radiation¹	Yes	10	100%	0.09	100%	0.47
Doxorubicin + radiation¹	No	27	88.7% (76.3–100)	0.09	96.3% (88.9–100)	0.47

EFS, Event -free survival; OS, overall survival

Excluding 2 patients who received either doxorubicin with no radiation or radiation with no doxorubicin

Log Rank test